AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
AI can make mistakes. Verify answers against the original sources before relying on them.
salsalate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| analgesic anti-inflammatory | 2420 | 552-94-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 3 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 100 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,ITK,JAK1,JAK2,KIT,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAPK1,MAPK12,MAPK7,MAPK8,MAPK9,MAPKAPK2,MARK4,MTOR,NTRK2,PDK1,PDK2,PDPK1,PIK3CB,PIK3CD,PIM2,PLK1,PRKCD,PRKDC,SGK1,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 | 57 | |||
| kinase-selectivity-class | ACVR2A,ACVR2B,AURKB,AURKC,AXL,BRAF,CDK4,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,JAK2,MAP2K3,MAP2K6,MAP3K14,MAPK1,MAPK12,MAPK7,MAPK8,MARK4,MTOR,PDK4,PIK3CD,PRKDC,SIK2,STK10,STK33,SYK,TEK,TGFBR1,TTK,ULK1 | 36 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| International normalised ratio increased | 36.91 | 29.16 | 15 | 423 | 48153 | 42572744 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| International normalised ratio increased | 28.35 | 27.51 | 13 | 712 | 86759 | 110501815 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N02BA06 | NERVOUS SYSTEM ANALGESICS OTHER ANALGESICS AND ANTIPYRETICS Salicylic acid and derivatives |
| MeSH PA | D000700 | Analgesics |
| MeSH PA | D000893 | Anti-Inflammatory Agents |
| MeSH PA | D000894 | Anti-Inflammatory Agents, Non-Steroidal |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D018501 | Antirheumatic Agents |
| MeSH PA | D018689 | Sensory System Agents |
| MeSH PA | D018712 | Analgesics, Non-Narcotic |
| CHEBI has role | CHEBI:35475 | non-steroidal anti-inflammatory drug |
| CHEBI has role | CHEBI:35480 | analgesic |
| CHEBI has role | CHEBI:35481 | non-narcotic analgesic |
| CHEBI has role | CHEBI:35526 | hypoglycemic agent |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:35625 | EC 3.5.2.6 (β-lactamase) inhibitor |
| CHEBI has role | CHEBI:35842 | antirheumatic drug |
| CHEBI has role | CHEBI:50266 | prodrug |
| CHEBI has role | CHEBI:50864 | insulin-sensitizing drug |
| CHEBI has role | CHEBI:74518 | anti-obesity agent |
| CHEBI has role | CHEBI:75835 | anti-anaemic agent |
| CHEBI has role | CHEBI:145947 | antiatherosclerotic agent |
| CHEBI has role | CHEBI:35441 | antiinfective agent |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:35718 | antifungal agent |
| CHEBI has role | CHEBI:37848 | plant hormone |
| CHEBI has role | CHEBI:50176 | keratolytic drug |
| CHEBI has role | CHEBI:50177 | dermatologic drug |
| CHEBI has role | CHEBI:50247 | antidote |
| CHEBI has role | CHEBI:50249 | anticoagulant |
| CHEBI has role | CHEBI:50748 | antipsoriatic |
| CHEBI has role | CHEBI:66981 | ophthalmology drug |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
| CHEBI has role | CHEBI:73181 | EC 1.11.1.11 (<small>L</small>-ascorbate peroxidase) inhibitor |
| CHEBI has role | CHEBI:76924 | plant metabolite |
| CHEBI has role | CHEBI:84735 | algal metabolite |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000935 | Antifungal Agents |
| MeSH PA | D003879 | Dermatologic Agents |
| MeSH PA | D007641 | Keratolytic Agents |
Related Drugs by ATC class:
N02BA Salicylic acid and derivatives 11 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Rheumatoid arthritis | indication | 69896004 | DOID:7148 |
| Osteoarthritis | indication | 396275006 | |
| Gastritis | contraindication | 4556007 | DOID:4029 |
| Gastrointestinal ulcer | contraindication | 40845000 | |
| Body fluid retention | contraindication | 43498006 | |
| Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
| Vitamin K deficiency | contraindication | 52675005 | DOID:11249 |
| Nasal polyp | contraindication | 52756005 | |
| Hepatic failure | contraindication | 59927004 | |
| Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Factor II deficiency | contraindication | 73975000 | |
| Gastrointestinal hemorrhage | contraindication | 74474003 | |
| Thrombotic thrombocytopenic purpura | contraindication | 78129009 | DOID:10772 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Thyrotoxicosis | contraindication | 90739004 | DOID:7997 |
| Hemophilia | contraindication | 90935002 | |
| Anemia due to enzyme deficiency | contraindication | 111577008 | |
| Gastroesophageal reflux disease | contraindication | 235595009 | DOID:8534 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Pregnancy, function | contraindication | 289908002 | |
| Cardiovascular event risk | contraindication | 395112001 | |
| Breastfeeding (mother) | contraindication | 413712001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.37 | acidic |
| pKa2 | 9.43 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 4018818 | VUID |
| N0000179234 | NUI |
| D00428 | KEGG_DRUG |
| 4018663 | VANDF |
| 4018818 | VANDF |
| C0073983 | UMLSCUI |
| CHEBI:9014 | CHEBI |
| SAL | PDB_CHEM_ID |
| CHEMBL154111 | ChEMBL_ID |
| DB01399 | DRUGBANK_ID |
| 5161 | PUBCHEM_CID |
| C014182 | MESH_SUPPLEMENTAL_RECORD_UI |
| 3267 | INN_ID |
| V9MO595C9I | UNII |
| 36108 | RXNORM |
| 1419 | MMSL |
| 5439 | MMSL |
| 5441 | MMSL |
| 9170 | MMSL |
| d00842 | MMSL |
| 001596 | NDDF |
| 001951 | NDDF |
| 13252002 | SNOMEDCT_US |
| 387072007 | SNOMEDCT_US |
| 387253001 | SNOMEDCT_US |
| 46741005 | SNOMEDCT_US |
| C0036079 | UMLSCUI |
| DB00936 | DRUGBANK_ID |
| 338 | PUBCHEM_CID |
| D020156 | MESH_DESCRIPTOR_UI |
| CHEBI:16914 | CHEBI |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Salsalate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-492 | TABLET, FILM COATED | 500 mg | ORAL | UNAPPROVED DRUG OTHER | 27 sections |
| Salsalate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-493 | TABLET, FILM COATED | 750 mg | ORAL | UNAPPROVED DRUG OTHER | 27 sections |
| Salsalate Rx | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13273-209 | TABLET, FILM COATED | 500 mg | ORAL | UNAPPROVED DRUG OTHER | 28 sections |
| Salsalate Rx | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13273-210 | TABLET, FILM COATED | 750 mg | ORAL | UNAPPROVED DRUG OTHER | 28 sections |
| Salsalate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-392 | TABLET | 750 mg | ORAL | Unapproved drug other | 28 sections |
| Salsalate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50682-507 | TABLET, FILM COATED | 500 mg | ORAL | Unapproved drug other | 25 sections |
| Salsalate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50682-508 | TABLET, FILM COATED | 750 mg | ORAL | Unapproved drug other | 25 sections |
| Salsalate | Human Prescription Drug Label | 1 | 57664-103 | TABLET | 500 mg | ORAL | Unapproved drug other | 28 sections |
| Salsalate | Human Prescription Drug Label | 1 | 57664-105 | TABLET | 750 mg | ORAL | Unapproved drug other | 28 sections |
| Salsalate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-512 | TABLET | 500 mg | ORAL | unapproved drug other | 16 sections |
| Salsalate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-513 | TABLET | 750 mg | ORAL | unapproved drug other | 16 sections |
| Salsalate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-1923 | TABLET | 500 mg | ORAL | Unapproved drug other | 14 sections |
| Salsalate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-1924 | TABLET | 750 mg | ORAL | Unapproved drug other | 14 sections |
| Salsalate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69367-615 | TABLET | 500 mg | ORAL | UNAPPROVED DRUG OTHER | 22 sections |
| Salsalate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69367-616 | TABLET | 750 mg | ORAL | UNAPPROVED DRUG OTHER | 22 sections |